CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” ...

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective cut by The Goldman Sachs Group from $66.00 to $57.00 ...

Analysts at William Blair reduced their Q1 2025 EPS estimates for CRISPR Therapeutics in a research note issued to investors ...

In trading on Friday, shares of CRISPR Therapeutics AG (Symbol: CRSP) crossed above their 200 day moving average of $49.55, changing hands as high as $52.60 per share. CRISPR Therapeutics AG ...

StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) to a sell rating in a research report released on Thursday. Other analysts have also issued reports about the stock.